drugset / Trial / NCT05846737
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
NaSingle-groupOpen-labelTreatment
Summary
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. A total of 40 subjects will be enrolled into this study.
Timeline
- Start
- 2023-05-29
- Primary completion
- 2025-05-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-BCMA CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-BCMA CAR-T | Cell therapy | 4e+06 cells/kg | Intravenous |